REGN Regeneron Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: REGN

Price (delayed)

$951.74

Market cap

$98.46B

P/E Ratio

20.25

Dividend/share

$3.7

EPS

$47.01

Enterprise value

$97.5B

?
Relative Growth: Rel. Growth: 84
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 46
Relative Profitability: Rel. Profitability: 87

Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine ...

Highlights
The revenue has increased by 19% YoY and by 9% QoQ
Regeneron Pharmaceuticals's gross profit has increased by 19% YoY and by 10% from the previous quarter
The quick ratio has contracted by 15% YoY but it has grown by 3.4% from the previous quarter
REGN's price to earnings (P/E) is 21% higher than its last 4 quarters average of 16.8 and 17% higher than its 5-year quarterly average of 17.4
Sector: Healthcare
Industry: Biotechnology
Website: http://www.regeneron.com
Peers: AMGN ALNY BIIB NVS

Key stats

What are the main financial stats of REGN

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time
Intraday
-0.8%
1 week
5.41%
1 month
24.77%
1 year
39.61%
YTD
23.3%
QTD
25.51%

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$16.9B
Gross profit
$14.49B
Operating income
$4.86B
Net income
$4.82B
Gross margin
85.8%
Net margin
28.5%
The operating income rose by 32% YoY and by 27% QoQ
The revenue has increased by 19% YoY and by 9% QoQ
Regeneron Pharmaceuticals's gross profit has increased by 19% YoY and by 10% from the previous quarter
Regeneron Pharmaceuticals's operating margin has increased by 17% QoQ and by 11% YoY

Price vs fundamentals

How does REGN's price correlate with its fundamentals

Growth

What is Regeneron Pharmaceuticals's growth rate over time

Valuation

What is Regeneron Pharmaceuticals stock price valuation
REGN P/E details
P/E
20.25
P/B
2.93
P/S
5.73
EV/EBIT
17.01
EV/EBITDA
15.61
EV/Sales
5.77
REGN's price to earnings (P/E) is 21% higher than its last 4 quarters average of 16.8 and 17% higher than its 5-year quarterly average of 17.4
The company's EPS rose by 12% QoQ and by 8% YoY
REGN's price to book (P/B) is 23% more than its last 4 quarters average of 2.4 but 4.8% less than its 5-year quarterly average of 3.1
The equity has grown by 8% year-on-year and by 6% since the previous quarter
The revenue has increased by 19% YoY and by 9% QoQ
The P/S is 18% higher than the last 4 quarters average of 4.9

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on equity has increased by 9% QoQ
Regeneron Pharmaceuticals's return on invested capital has increased by 9% QoQ and by 6% YoY
The return on assets has increased by 8% since the previous quarter but it has declined by 3.4% year-on-year
The company's return on sales fell by 7% YoY

Dividends

What is REGN's dividend history
Dividend details
DPS
$3.7
Dividend yield
0.39%
Payout ratio
7.9%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Regeneron Pharmaceuticals financials performed over time
Regeneron Pharmaceuticals's total liabilities has increased by 18% YoY and by 9% QoQ
The current ratio is down by 17% YoY
The debt is 92% less than the equity
REGN's debt to equity is down by 11% from the previous quarter and by 11% YoY
The equity has grown by 8% year-on-year and by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.